

# Information for adult patients prescribed XGEVA<sup>®</sup> (denosumab) for the prevention of skeletal-related events caused by bone metastases

## PATIENT INFORMATION

---

To access our patient website go to <https://www.amgencare.co.uk/xgeva> or scan the following QR code



Patient name	
Patient contact details	
Emergency contact details	
Specialist contact details	
GP contact details	
Nurse contact details	
Notes	





Patients undergoing chemotherapy and/or radiotherapy, taking steroids or anti-angiogenic medicines (used to treat cancer), undergoing dental surgery, who do not receive routine dental care, have gum disease, or who are smokers, may have a higher risk of developing ONJ.<sup>2,3</sup>

**While being treated:**

- You should maintain good oral hygiene and receive routine dental check-ups. If you wear dentures you should make sure these fit properly.
- If you are receiving dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor and tell your dentist that you are being treated with denosumab.

You should contact your doctor and dentist immediately if you experience any problems with your mouth or teeth, such as loose teeth, pain or swelling, and non-healing of sores or discharge, as these could be signs of ONJ.

Please note: Denosumab is not recommended for use in pregnancy or in women of child-bearing potential not using contraception.

For information about other possible side effects not mentioned in this booklet, please refer to the **Patient Information Leaflet**.



## REPORTING OF SIDE EFFECTS

If you get any side effects, talk to your doctor, pharmacist, or nurse.

This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple Store.

By reporting side effects you can help provide more information on the safety of this medicine.

Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441.

If you have any questions not answered by this leaflet, please contact your doctor:

Doctor's name

Doctor's number

**Further resources:**

**Cancer Research UK**  
Tel: 020 7242 0200

**Macmillan Cancer Support**  
Tel: 0300 123 1022



## REFERENCES

1. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med.* 2004;350:1655–1664.
2. XGEVA® (denosumab) vial, Patient Information Leaflet, Amgen.
3. XGEVA® (denosumab) pre-filled syringe, Patient Information Leaflet, Amgen.
4. XGEVA® (denosumab) Patient Reminder Card.

Amgen Ltd.  
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, United Kingdom  
[www.amgen.co.uk](http://www.amgen.co.uk)

©2024 Amgen Inc. All rights reserved.  
GBR-162X-0224-80005 - March 2024

**AMGEN**